What the FDA labels say about taking them together
Carbamazepine and osilodrostat
Osilodrostat's FDA label of November 18, 2025 names carbamazepine in its drug interactions section; the carbamazepine labels PlainMeds reads (3) do not name osilodrostat. The osilodrostat label: “Concomitant use of ISTURISA with strong CYP3A4 and/or CYP2B6 inducers may cause a decrease in osilodrostat concentration and may reduce the efficacy of ISTURISA. …”
Check it at the source: the carbamazepine FDA label on DailyMed (effective August 20, 2026, Novartis Pharmaceuticals Corporation); the osilodrostat FDA label on DailyMed (effective November 18, 2025, Recordati Rare Diseases, Inc.).
What does the carbamazepine label say about osilodrostat?
Carbamazepine's label (effective August 20, 2026) and its 2 other brand-application labels do not name osilodrostat in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Tegretol), Novartis Pharmaceuticals Corporation, effective August 20, 2026 (SPL set 8d409411-aa9f-4f3a-a52c-fbcb0c3ec053), via openFDA; the full label on DailyMed
What does the osilodrostat label say about carbamazepine?
Osilodrostat label, drug interactionsCYP3A4 and CYP2B6 Inducers Clinical Impact: Concomitant use of ISTURISA with strong CYP3A4 and/or CYP2B6 inducers (…) may cause a decrease in osilodrostat concentration and may reduce the efficacy of ISTURISA. Discontinuation of strong CYP3A4 and/or CYP2B6 inducers while using ISTURISA may cause an increase in osilodrostat concentration and may increase the risk of … Intervention: During concomitant use of ISTURISA with strong CYP3A4 and CYP2B6 inducers, monitor cortisol concentration and patient's signs and symptoms. An increase in ISTURISA dosage may be needed. …
Source: FDA drug label (Isturisa), Recordati Rare Diseases, Inc., effective November 18, 2025 (SPL set f3a5ec24-63c3-4d83-b1c0-6c550fbe7ae2), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Carbamazepine | Osilodrostat | |
|---|---|---|
| Labeled for | Bipolar disorder, Seizures and epilepsy | n/a |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $0.119 per tablet 200 mg tablet | n/a |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once